Artificial pancreas smart, future for diabetics

With this new device, the patient will get out of the syringe, getting rid of all worries about insulin levels causing the risk of hypoglycemia.

Diabeloop, a French start-up company is about to launch the world's first artificial pancreas market . In the premiere before the new media, Erik Huneker, founder of Diabeloop, said the device was designed for type 1 diabetics and is now CE certified by Europe. This is a certification for products that are healthy, safe and environmentally friendly.

The entire artificial pancreas DBL1, includes an automatic insulin-level pump, a blood sugar monitor sensor and a pocket-sized operating system just as small as a phone.

It is known that in France alone, up to 10% of patients with type 1 diabetes out of all diabetes patients, about 300,000 people. With this new device, from now on these people will get out of the syringe, getting rid of any worries about insulin levels that pose a risk of hypoglycemia that can lead to coma or the risk of long-term serious complications .

The device, called "DBLG1 System" , consists of a pump just as small as a matchbox but thinner than the arm and a sensor placed in the abdominal cavity.

Through Bluetooth connectivity, information on blood sugar is transmitted to the third part of the artificial pancreas, located in the patient's pocket. This is a sophisticated and personalized smartphone that is responsible for analyzing information from sensors with complex algorithms taking into account different parameters (patient weight, impact of insulin speed .) and blood sugar so that the pump automatically adjusts the insulin dose needed.

In clinical trials of 36 type 1 diabetics in 9 different medical centers in France and 60 other patients outside the hospital, DBLG1 proved excellent. GS. Eric Renard, coordinator of the Department of Endocrinology, Diabetes and Nutrition at Montpellier University Hospital, said the experiments are aimed at ensuring that every patient knows how to use the device properly. and easy.

The device is extremely simple, just mount on the body and put into the operating system pocket.

Currently Diabeloop is planning to commercialize DB1 in the first quarter of 2019 not only in Europe but also internationally. In parallel, they will also continue to research and develop new versions with simpler sensors for non-standard, non-sensitive paracetamol patients.

In addition, in the first version, DBLG1 was only designed for adults, so they will adjust algorithms, software development as well as clinical trials of other versions for teenagers aged 13-18 age and next version for ages 6 - 12.

However, Diabeloop also added, in order to get DBLG1, it is necessary to have a prescription from a diabetes specialist and the patient must go to the hospital to be set up.